Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10022444
APP PUB NO 20160339101A1
SERIAL NO

15231185

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ASTELLAS PHARMA INC5-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU TOKYO 1038411 ?1038411

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Heinz, Cornelia Adriana Maria Dalheim, DE 7 37
Jacobs, Stefan Denis Mainz-Kastel, DE 7 37
Mitnacht-Kraus, Rita Friedberg, DE 24 162
Sahin, Ugur Mainz, DE 331 2329
Stadler, Christiane Regina Bensheim, DE 7 37
Tureci, Ozlem Mainz, DE 106 1073
Utsch, Magdalena Jadwiga Heidesheim am Rhein, DE 7 37

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 17, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 17, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00